References (Continued)
21. Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi160–170.
Continue Reading
22. Dima D, Tomuleasa C, Frinc I, et al. The use of rotation to fentanyl in cancer-related pain. J Pain Res. 2017;10:341–348.
23. Huser M, Smardova L, Ventruba P, Mayer J. [Impact of oncological treatment on human reproduction]. Klin Onkol. 2010;23(3):165–170.
24. Huser M, Zakova J, Smardova L, et al. Combination of fertility preservation strategies in young women with recently diagnosed cancer. Eur J Gynaecol Oncol. 2012;33(1):42–50.
25. Vlad C, Kubelac P, Onisim A, et al. Expression of CDCP1 and ADAM12 in the ovarian cancer microenvironment. J BUON. 2016;21(4):973–978.
26. Bochis OV, Fetica B, Vlad C, Achimas-Cadariu P, Irimie A. The importance of ubiquitin E3 ligases, SCF and APC/C, in human cancers. Clujul Med. 2015;88(1):9–14.
27. Irimie AI, Braicu C, Pileczki V, et al. Knocking down of p53 triggers apoptosis and autophagy, concomitantly with inhibition of migration on SSC-4 oral squamous carcinoma cells. Mol Cell Biochem. 2016;419(1–2):75–82.
28. Frinc I, Muresan MS, Zaharie F, et al. Cancer stem-like cells: the dark knights of clinical hematology and oncology. J BUON. 2014;19(2):328–335.
29. Hu Q, Hong L, Nie M, et al. The effect of dehydroepiandrosterone supplementation on ovarian response is associated with androgen receptor in diminished ovarian reserve women. J Ovarian Res. 2017;10(1):32.
30. Irimie A, Achimas-Cadariu P, Burz C, Puscas E. Multiple primary malignancies–epidemiological analysis at a single tertiary institution. J Gastrointestin Liver Dis. 2010;19(1):69–73.
31. Kubelac MP, Fetica B, Vlad IC, Fulop A, Popa A, Achimas-Cadariu P. The role of inhibitor of DNA-binding 1 (ID-1) protein and angiogenesis in serous ovarian cancer. Anticancer Res. 2014;34(1):413–416.
32. Vlad C, Kubelac P, Onisim A, Irimie A, Achimas-Cadariu P. The role of CDCP1 (CUB domain-containing protein 1) and ADAM12 (a disintegrin and metalloproteinase 12) in ovarian cancer. J BUON. 2015;20(3):673–679.
33. Gherman C, Braicu OL, Zanoaga O, et al. Caffeic acid phenethyl ester activates pro-apoptotic and epithelial-mesenchymal transition-related genes in ovarian cancer cells A2780 and A2780cis. Mol Cell Biochem. 2016;413(1–2):189–198.
34. Haukvik UK, Dieset I, Bjoro T, Holte H, Fossa SD. Treatment-related premature ovarian failure as a long-term complication after Hodgkin’s lymphoma. Ann Oncol. 2006;17(9):1428–1433.
35. Zheng Y, Thomas A, Schmidt CM, Dann CT. Quantitative detection of human spermatogonia for optimization of spermatogonial stem cell culture. Hum Reprod. 2014;29(11):2497–2511.
36. van der Kaaij MA, Heutte N, van Echten-Arends J, et al. Sperm quality before treatment in patients with early stage Hodgkin’s lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica. 2009;94(12):1691–1697.
37. Anselmo AP, Cartoni C, Bellantuono P, Maurizi-Enrici R, Aboulkair N, Ermini M. Risk of infertility in patients with Hodgkin’s disease treated with ABVD vs MOPP vs ABVD/MOPP. Haematologica. 1990;75(2):155–158.
38. Bonfante V, Santoro A, Viviani S, Valagussa P, Bonadonna G. ABVD in the treatment of Hodgkin’s disease. Semin Oncol. 1992;19(2 Suppl 5):38–44; discussion 44–45.
39. Hodgson DC, Pintilie M, Gitterman L, et al. Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol. 2007;25(1):11–15.
40. Brusamolino E, Baio A, Orlandi E, et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin’s lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res. 2006;12(21):6487–6493.
41. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2005;23(30):7555–7564.
42. Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D. Anti-Mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online. 2010;20(2):280–285.
43. Yuksel A, Bildik G, Senbabaoglu F, et al. The magnitude of gonadotoxicity of chemotherapy drugs on ovarian follicles and granulosa cells varies depending upon the category of the drugs and the type of granulosa cells. Hum Reprod. 2015;30(12):2926–2935.
44. Lambertini M, Del Mastro L, Viglietti G, Ponde NF, Solinas C, de Azambuja E. Ovarian function suppression in pemenopausal women with early-stage breast cancer. Curr Treat Options Oncol. 2017;18(1):4.
45. Harel S, Ferme C, Poirot C. Management of fertility in patients treated for Hodgkin’s lymphoma. Haematologica. 2011;96(11):1692–1699.
46. Leroy C, Rigot JM, Leroy M, et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis. 2015;10:136.
47. Loren AW. Fertility issues in patients with hematologic malignancies. Hematology Am Soc Hematol Educ Program. 2015;2015:138–145.
48. Ash P. The influence of radiation on fertility in man. Br J Radiol. 1980;53(628):271–278.
49. Nakayama K, Liu P, Detry M, et al. Receiving information on fertility- and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation: changes in perceived importance over time. Biol Blood Marrow Transplant. 2009;15(11):1465–1474.
50. Swerdlow AJ, Cooke R, Bates A, et al. Risk of premature menopause after treatment for Hodgkin’s lymphoma. J Natl Cancer Inst. 2014;106(9).
51. de Bruin ML, Huisbrink J, Hauptmann M, et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood. 2008;111(1):101–108.
52. Kapke JT, Epperla N, Shah N, et al. Effect of routine surveillance imaging on the outcomes of patients with classical Hodgkin lymphoma after autologous hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk. 2017;17(7):408–414.
53. Wilke C, Cao Q, Dusenbery KE, et al. Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2017;99(1):94–102.
54. Padberg S, Mick I, Frenzel C, Greil R, Hilberath J, Schaefer C. Transient congenital dilated cardiomyopathy after maternal R-CHOP chemotherapy during pregnancy. Reprod Toxicol. 2017;71:146–149.
55. Bragnes Y, Boshuizen R, de Vries A, Lexberg A, Ostensen M. Low level of Rituximab in human breast milk in a patient treated during lactation. Rheumatology. 2017;56(6):1047–1048.
56. Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566.
57. Bair SM, Strelec L, Nagle SJ, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis. Am J Hematol. 2017;92(9):879–884.
58. Gafencu GA, Selicean SE, Petrushev B, et al. Clinicopathological analysis of a case series of peripheral T-cell lymphomas, not otherwise specified, of lymphoepithelioid variant (Lennert’s lymphoma). A Central European single-center study. Hum Pathol. 2016;53:192–194.
59. Dima D, Tomuleasa C, Irimie A, et al. Magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab. Cancer. 2014;120(24):4005–4006.
60. Ansell SM. Brentuximab vedotin. Blood. 2014;124(22):3197–3200.
61. Scott LJ. Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma. Drugs. 2017;77(4):435–445.
62. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–1862.
63. Kanematsu D, Shofuda T, Yamamoto A, et al. Isolation and cellular properties of mesenchymal cells derived from the decidua of human term placenta. Differentiation. 2011;82(2):77–88.
64. Onisim A, Achimas-Cadariu A, Vlad C, Kubelac P, Achimas-Cadariu P. Current insights into the association of Nestin with tumor angiogenesis. J BUON. 2015;20(3):699–706.
65. Flerlage JE, Metzger ML, Wu J, Panetta JC. Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma. Cancer Chemother Pharmacol. 2016;78(6):1217–1223.
66. Ansell SM. Nivolumab in the treatment of Hodgkin lymphoma. Clin Cancer Res. 2017;23(7):1623–1626.
67. Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–2704.
68. Merryman RW, Kim HT, Zinzani PL, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017;129(10):1380–1388.
69. Lin RJ, Diefenbach CS. Checkpoint inhibition in Hodgkin lymphoma: saving the best for last? Oncology (Williston Park). 2016;30(10):914–920.
70. Pembrolizumab approved for Hodgkin lymphoma. Cancer Discov. 2017;7(5):OF1.
71. Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–2132.
72. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733–3739.
73. Ellinger I, Fuchs R. HFcRn-mediated transplacental immunoglobulin G transport: protection of and threat to the human fetus and newborn. Wien Med Wochenschr. 2012;162(9–10):207–213.
74. Warrington JP, Drummond HA, Granger JP, Ryan MJ. Placental ischemia-induced increases in brain water content and cerebrovascular permeability: role of TNF-α. Am J Physiol Regul Integr Comp Physiol. 2015;309(11):R1425–1431.
75. Pfreundschuh M, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). High-dose chemotherapy and autologous stem-cell transplantation for DLBCL in the rituximab era. Lancet Oncol. 2017;18(8):989–991.
76. Della Pepa R, Picardi M, Giordano C, et al. Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2017. [Epub ahead of print].
77. Tomuleasa C, Braicu C, Irimie A, Craciun L, Berindan-Neagoe I. Nanopharmacology in translational hematology and oncology. Int J Nanomedicine. 2014;9:3465–3479.
78. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–1506.
79. Thurn L, Lindqvist PG, Jakobsson M, et al. Abstracts of the 26th World Congress on Ultrasound in Obstetrics and Gynecology, Rome, Italy, 24–28 September 2016. Ultrasound Obstet Gynecol. 2016;48(Suppl 1):140.
80. Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20(5):688–701.
81. Gultekin M, Dursun P, Vranes B, et al. Gynecologic oncology training systems in Europe: a report from the European network of young gynaecological oncologists. Int J Gynecol Cancer. 2011;21(8):1500–1506.
82. Ordeanu C, Pop DC, Badea R, et al. Local experience in cervical cancer imaging: Comparison in tumour assessment between TRUS and MRI. Rep Pract Oncol Radiother. 2015;20(3):223–230.
83. Mahany EB, Randolph JF Jr. Biochemical and imaging diagnostics in endocrinology: predictors of fertility. Endocrinol Metab Clinics North Am. 2017;46(3):679–689.
84. Iraha Y, Okada M, Iraha R, et al. CT and MR imaging of gynecologic emergencies. Radiographics. 2017;37(5):1569–1586.
85. Lambertini M, Cinquini M, Moschetti I, et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer. 2017;71:25–33.
86. Bedaiwy MA, Allaire C, Alfaraj S. Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. Fertil Steril. 2017;107(3):537–548.
87. Huser M, Smardova L, Janku P, et al. Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analogues. J Assist Reprod Genet. 2015;32(8):1187–1193.
88. Falorio S, Angrilli F, Fioritoni G. Gonadotropin-releasing hormone analog treatment for the prevention of treatment-related ovarian failure and infertility in women of reproductive age with Hodgkin lymphoma. Leuk Lymphoma. 2008;49(6):1087–1093.
89. Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe JM, Dann EJ. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril. 2008;89(1):166–173.
90. Nitzschke M, Raddatz J, Bohlmann MK, Stute P, Strowitzki T, von Wolff M. GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin’s lymphoma patients. Arch Gynecol Obstet. 2010;282(1):83–88.
91. Behringer K, Wildt L, Mueller H, et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol. 2010;21(10):2052–2060.
92. Sonigo C, Seroka A, Cedrin-Durnerin I, Sermondade N, Sifer C, Grynberg M. History of ABVD alters the number of oocytes vitrified after in vitro maturation in fertility preservation candidates. Future Oncol. 2016;12(14):1713–1719.
93. Alvarez RM, Ramanathan P. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response. Hum Reprod. 2016; pii: dew158. [Epub ahead of print].
94. Dahhan T, Balkenende EME, Beerendonk CCM, et al. Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial. Contemp Clin Trials. 2017;61:96–100.
95. Pereira N, Hubschmann AG, Lekovich JP, Schattman GL, Rosenwaks Z. Ex vivo retrieval and cryopreservation of oocytes from oophorectomized specimens for fertility preservation in a BRCA1 mutation carrier with ovarian cancer. Fertil Steril. 2017;108(2):357–360.
96. Rienzi L, Cobo A, Paffoni A, et al. Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study. Hum Reprod. 2012;27(6):1606–1612.
97. Donnez J, Martinez-Madrid B, Jadoul P, Van Langendonckt A, Demylle D, Dolmans MM. Ovarian tissue cryopreservation and transplantation: a review. Hum Reprod Update. 2006;12(5):519–535.
98. Binesh F, Akhavan A, Behniafard N, Atefi A. Clinicopathologic and survival characteristics of childhood and adolescent non Hodgkin’s lymphoma in Yazd, Iran. Asian Pac J Cancer Prev. 2014;15(4):1585–1588.
99. Anselmo AP, Cavalieri E, Aragona C, Sbracia M, Funaro D, Maurizi Enrici R. Successful pregnancies following an egg donation program in women with previously treated Hodgkin’s disease. Haematologica. 2001;86(6):624–628.
100. Evenson DP, Jost LK, Marshall D, et al. Utility of the sperm chromatin structure assay as a diagnostic and prognostic tool in the human fertility clinic. Hum Reprod. 1999;14(4):1039–49.
101. Sergerie M, Laforest G, Bujan L, Bissonnette F, Bleau G. Sperm DNA fragmentation: threshold value in male fertility. Hum Reprod. 2005;20(12):3446–3451.
102. Morris ID, Ilott S, Dixon L, Brison DR. The spectrum of DNA damage in human sperm assessed by single cell gel electrophoresis (Comet assay) and its relationship to fertilization and embryo development. Hum Reprod. 2002;17(4):990–998.
103. Zubkova EV, Wade M, Robaire B. Changes in spermatozoal chromatin packaging and susceptibility to oxidative challenge during aging. Fertil Steril. 2005;84(Suppl 2):1191–1198.
104. Redig AJ, Brannigan R, Stryker SJ, Woodruff TK, Jeruss JS. Incorporating fertility preservation into the care of young oncology patients. Cancer. 2011;117(1):4–10.
105. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr. 2005;(34):12–17.
106. Sieniawski M, Reineke T, Josting A, et al. Assessment of male fertility in patients with Hodgkin’s lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol. 2008;19(10):1795–1801.
107. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–2510.
108. Sucala M, Cuijpers P, Muench F, et al. Anxiety: there is an app for that. A systematic review of anxiety apps. Depress Anxiety. 2017;34(6):518–525.
109. Tomuleasa C, Zaharie F, Muresan MS, et al. How to diagnose and treat a cancer of unknown primary site. J Gastrointest Liver Dis. 2017;26(1):69–79.
110. Braicu C, Chiorean R, Irimie A, et al. Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy. Expert Rev Mol Med. 2016;18:e18.
111. Frinc I, Ilies P, Zaharie F, et al. Transthoracic ultrasonography for the immunocompromised patient. A pilot project that introduces transthoracic ultrasonography for the follow-up of hematological patients in Romania. Rom J Intern Med. 2017;55(2):103–116.
112. Micu R, Petrut B, Zlatescu-Marton C, Traila A, Harsa R, Achimas-Cadariu P. Current strategies and future perspectives in fertility preservation for cancer patients. J BUON. 2017;22(4):844–852.
113. Truta Z, Garlovanu M, Lerintiu S, Micu R. A new method for human semen glucose concentration evaluation. Rom Biotech Lett. 2010;15:5764–5772.
Source: Cancer Management and Research.
Originally published DATE.
